Literature DB >> 11836397

Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simplex virus type 1 in mice.

Robert K Tran1, Pauline T Lieu, Santiago Aguilar, Edward K Wagner, David C Bloom.   

Abstract

While many herpes simplex virus (HSV) structural proteins are expressed with strict-late kinetics, the HSV virion protein 5 (VP5) is expressed as a "leaky-late" protein, such that appreciable amounts of VP5 are made prior to DNA replication. Our goal has been to determine if leaky-late expression of VP5 is a requirement for a normal HSV infection. It had been shown previously that recombinant viruses in which the VP5 promoter was replaced with promoters of other kinetic classes (including a strict late promoter) exhibited no alterations in replication kinetics or virus yields in vitro. In contrast, here we report that alterations in pathogenesis were observed when these recombinants were analyzed by experimental infection of mice. Following intracranial inoculation, a recombinant expressing VP5 from a strict-late promoter (U(L)38) exhibited an increased 50% lethal dose and a 10-fold decrease in virus yields in the central nervous system, while a recombinant expressing VP5 from an early (dUTPase) or another leaky-late (VP16) promoter exhibited wild-type neurovirulence. Moreover, following infection of the footpad, changing the expression kinetics of VP5 from leaky-late to strict-late resulted in 100-fold-less virus in the spinal ganglia during the acute infection than produced by either the parent virus or the rescued virus. These data indicate that the precise timing of appearance of the major capsid protein plays a role in the pathogenesis of HSV infections and that changing the expression kinetics has different effects in different cell types and tissues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11836397      PMCID: PMC153803          DOI: 10.1128/jvi.76.5.2199-2205.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  The kinetics of VP5 mRNA expression is not critical for viral replication in cultured cells.

Authors:  P T Lieu; E K Wagner
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Mutations in the N-terminus of VP5 alter its interaction with the scaffold proteins of herpes simplex virus type 1.

Authors:  S C Warner; G Chytrova; P Desai; S Person
Journal:  Virology       Date:  2001-06-05       Impact factor: 3.616

3.  A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice.

Authors:  E Pelosi; F Rozenberg; D M Coen; K L Tyler
Journal:  Virology       Date:  1998-12-20       Impact factor: 3.616

4.  Capsids are formed in a mutant virus blocked at the maturation site of the UL26 and UL26.5 open reading frames of herpes simplex virus type 1 but are not formed in a null mutant of UL38 (VP19C).

Authors:  S Person; P Desai
Journal:  Virology       Date:  1998-03-01       Impact factor: 3.616

5.  Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA.

Authors:  P Desai; N A DeLuca; J C Glorioso; S Person
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

Review 6.  Transcription of the herpes simplex virus genome during productive and latent infection.

Authors:  E K Wagner; J F Guzowski; J Singh
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1995

7.  The exchange of cognate TATA boxes results in a corresponding change in the strength of two HSV-1 early promoters.

Authors:  P T Lieu; N T Pande; M K Rice; E K Wagner
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

8.  Neuron-specific restriction of a herpes simplex virus recombinant maps to the UL5 gene.

Authors:  D C Bloom; J G Stevens
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice.

Authors:  P Desai; N A DeLuca; S Person
Journal:  Virology       Date:  1998-07-20       Impact factor: 3.616

10.  Expression of herpes simplex virus beta and gamma genes integrated in mammalian cells and their induction by an alpha gene product.

Authors:  R M Sandri-Goldin; A L Goldin; L E Holland; J C Glorioso; M Levine
Journal:  Mol Cell Biol       Date:  1983-11       Impact factor: 4.272

View more
  8 in total

1.  ICP27 selectively regulates the cytoplasmic localization of a subset of viral transcripts in herpes simplex virus type 1-infected cells.

Authors:  Angela Pearson; David M Knipe; Donald M Coen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

2.  Wide variations in herpes simplex virus type 1 inoculum dose and latency-associated transcript expression phenotype do not alter the establishment of latency in the rabbit eye model.

Authors:  J E O'Neil; J M Loutsch; J S Aguilar; J M Hill; E K Wagner; D C Bloom
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

3.  Immediate-early expression of the herpes simplex virus type 1 ICP27 transcript is not critical for efficient replication in vitro or in vivo.

Authors:  Aixu Sun; G V Devi-Rao; M K Rice; L W Gary; D C Bloom; R M Sandri-Goldin; P Ghazal; E K Wagner
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice.

Authors:  Gary D Luker; J Patrick Bardill; Julie L Prior; Christina M Pica; David Piwnica-Worms; David A Leib
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.

Authors:  Terri G Edwards; David C Bloom; Chris Fisher
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

6.  The TATGARAT box of the HSV-1 ICP27 gene is essential for immediate early expression but not critical for efficient replication in vitro or in vivo.

Authors:  Aixu Sun; G V Devi-Rao; M K Rice; L W Gary; D C Bloom; R M Sandri-Goldin; P Wagner; E K Wager
Journal:  Virus Genes       Date:  2004-12       Impact factor: 2.332

7.  Reduction in severity of a herpes simplex virus type 1 murine infection by treatment with a ribozyme targeting the UL20 gene RNA.

Authors:  Jia Liu; Alfred S Lewin; Sonal S Tuli; Steven C Ghivizzani; Gregory S Schultz; David C Bloom
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

8.  De novo synthesis of VP16 coordinates the exit from HSV latency in vivo.

Authors:  Richard L Thompson; Chris M Preston; Nancy M Sawtell
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.